Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHARM-03: Maraviroc Gel and Oral Maraviroc PK/Safety
NCT02346084Phase 1Completed
- Sponsor
- International Partnership for Microbicides
- Start
- Jan 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of maraviroc in human immunodeficiency virus infection (HIV) (2 arms), sponsored by International Partnership for Microbicides. Primary endpoint: Adverse Events Grade 2 or higher at 9 months. Started Jan 2015; status: completed.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02346084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02346084.